Evoke Pharma (EVOK) Stock Price, Quote & News

Company Profile

Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was i...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 858 345 1494

Website: www.evokepharma.com

Address:

420 Stevens Avenue, Suite 230, Solana Beach, United States

CPA1982 Dec. 13 at 3:52 PM

$EVOK Has anyone heard of, or been contacted by attorneys about suing Evoke's board for breach of fiduciary duties, among other things. I googled Evoke Pharma lawsuits and it looks like there are some law firms that may be investigating the possibility of lawsuits. Just curious.

0 · Reply

TwongStocks Dec. 11 at 10:15 PM

$EVOK Equity Corporate Actions Alert #2025 - 679 Information Regarding the Tender Offer of Evoke Pharma, Inc. (EVOK) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-679 The tender offer by QOL Medical, LLC to acquire all of the outstanding common stock of Evoke Pharma, Inc. (EVOK) is scheduled to expire one minute after 11:59 p.m. ET, on December 15, 2025, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on December 17, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on December 16, 2025. If the merger closes as planned, the stock will remain halted on the day of closing (December 17th) and will be suspended effective December 18, 2025.

0 · Reply

HypnoTrader Dec. 10 at 2:53 PM

$EVOK if 50%+ shares are tendered, buyer gets control and sale is forced for all shares.

1 · Reply

theitaliantrader Dec. 10 at 1:41 PM

$EVOK what happens to my share if i don't want to sell at 11$?

0 · Reply

podcaster1 Dec. 1 at 6:04 PM

$JTAI $AXTA $COMP $EVOK They only show up when a deal terms look juicy enough that someone thinks shareholders might be leaving money on the table. These alerts happen every deal. Lawyer ad = someone smells value.

0 · Reply

Daddydoyouright Nov. 19 at 12:28 PM

$EVOK what happen here

1 · Reply

xbaz Nov. 17 at 4:15 PM

$EVOK i got fked by this company badly

1 · Reply

ACInvestorBlog Nov. 9 at 4:52 PM

$VVOS Considering how far the stock has fallen a rebound could mean a big move up for this stock. Keep an eye on it. Vivos Therapeutics is a medical technology company specializing in non-invasive treatments for obstructive sleep apnea (OSA). OSA affects more than 1 billion people globally, with U.S. prevalence at 30 million adults and rising pediatric cases. Vivos targets the $5B+ U.S. sleep market, with Medicare reimbursement, new CPT codes, and 2025 acquisitions (e.g., Sleep Center of Nevada adding 3,000 patients/month) boosting scalability. Revenue grew 9% in 2024, with product sales up 87% YoY in early 2025 and analysts project positive cash flow by year-end. Im long on this name. I hope for an $EVOK type scenario :)

0 · Reply

PaulLaurent Nov. 8 at 8:02 PM

🚀📈 Top Gainers 📈🚀 Last Week $MTC $TERN $MAMK $EVOK $FRGE

0 · Reply

Daddydoyouright Nov. 6 at 2:33 PM

$EVOK sell or wait ?

0 · Reply

Evoke assesses Italian unit sale amid tax concerns ahead of budget, Sky News reports

Nov 3, 2025, 9:08 AM EST - 5 weeks ago

MAI Capital Management Announces Expanded Office of Managing Partners Appointments Following Strategic Acquisition of Evoke Advisors

Oct 3, 2025, 9:08 AM EDT - 2 months ago

Evoke Advisors Ranked No. 1 on Forbes' ‘America's Top RIA Firms' List for Fourth Consecutive Year

Aug 27, 2025, 9:30 AM EDT - 3 months ago

MAI Capital Management Announces Strategic Partnership with Evoke Advisors

Aug 26, 2025, 7:00 AM EDT - 3 months ago

Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship

Aug 21, 2025, 7:00 AM EDT - 4 months ago

Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book

Aug 6, 2025, 6:30 AM EDT - 4 months ago

Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038

Jul 9, 2025, 8:16 AM EDT - 5 months ago

Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036

May 13, 2025, 4:05 PM EDT - 7 months ago

Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 28, 2025, 8:30 AM EDT - 8 months ago

Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025

Mar 13, 2025, 8:36 PM EDT - 9 months ago

Evoke Pharma, Inc. (EVOK) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 4:02 PM EDT - 9 months ago

Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 6, 2025, 8:30 AM EST - 10 months ago

Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025

Feb 24, 2025, 8:30 AM EST - 10 months ago

Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors

Dec 19, 2024, 8:30 AM EST - 1 year ago

Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends

Dec 3, 2024, 8:30 AM EST - 1 year ago

Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI®

Nov 14, 2024, 8:00 AM EST - 1 year ago

InvestCloud to Partner with Evoke Advisors to Transform Their Digital Experience

Nov 7, 2024, 4:05 PM EST - 1 year ago

Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results

Oct 28, 2024, 12:34 PM EDT - 1 year ago

Evoke Pharma stock surges over 100%—here's why

Oct 23, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting

Oct 22, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors

Oct 1, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion

Sep 19, 2024, 2:20 PM EDT - 1 year ago

Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments

Sep 18, 2024, 4:00 PM EDT - 1 year ago

XLR8 America and EVoke Systems Partner to Deliver Smarter EV Charging Stations to the Parking Industry

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference

Sep 4, 2024, 9:20 AM EDT - 1 year ago

Evoke Pharma to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma, Inc. Supports Gastroparesis Awareness Month

Jul 30, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma, Inc. Announces Reverse Stock Split

Jun 17, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI

May 16, 2024, 4:02 PM EDT - 1 year ago

Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference

May 14, 2024, 4:15 PM EDT - 1 year ago

Evoke Pharma Reports First Quarter 2024 Financial Results

Apr 17, 2024, 8:30 AM EDT - 1 year ago

Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications

Mar 21, 2024, 4:15 PM EDT - 1 year ago

Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer

Mar 14, 2024, 9:33 PM EDT - 1 year ago

Evoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 4:05 PM EDT - 1 year ago

Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 7, 2024, 4:10 PM EST - 1 year ago

Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024

Feb 14, 2024, 7:30 AM EST - 1 year ago

Evoke Pharma Announces Closing of $7.5 Million Public Offering

Feb 9, 2024, 7:30 AM EST - 2 years ago

Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million

Jan 29, 2024, 9:00 AM EST - 2 years ago

Kestra Private Wealth Services Announces New Partnership Between Maven Bridge Capital and Evoke Wealth Management

Nov 27, 2023, 8:30 AM EST - 2 years ago

Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent

Nov 14, 2023, 8:30 AM EST - 2 years ago

United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI

Nov 9, 2023, 8:30 AM EST - 2 years ago

Evoke Pharma Reports Third Quarter 2023 Financial Results

Oct 31, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023

Oct 18, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma's Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 An

Sep 14, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®

Aug 10, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma Reports Second Quarter 2023 Financial Results

Aug 7, 2023, 8:30 AM EDT - 2 years ago

Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting

CPA1982 Dec. 13 at 3:52 PM

0 · Reply

TwongStocks Dec. 11 at 10:15 PM

0 · Reply

HypnoTrader Dec. 10 at 2:53 PM

$EVOK if 50%+ shares are tendered, buyer gets control and sale is forced for all shares.

1 · Reply

theitaliantrader Dec. 10 at 1:41 PM

$EVOK what happens to my share if i don't want to sell at 11$?

0 · Reply

podcaster1 Dec. 1 at 6:04 PM

0 · Reply

Daddydoyouright Nov. 19 at 12:28 PM

$EVOK what happen here

1 · Reply

xbaz Nov. 17 at 4:15 PM

$EVOK i got fked by this company badly

1 · Reply

ACInvestorBlog Nov. 9 at 4:52 PM

0 · Reply

PaulLaurent Nov. 8 at 8:02 PM

🚀📈 Top Gainers 📈🚀 Last Week $MTC $TERN $MAMK $EVOK $FRGE

0 · Reply

Daddydoyouright Nov. 6 at 2:33 PM

$EVOK sell or wait ?

0 · Reply

jwdnl33 Nov. 5 at 6:51 PM

$EVOK never held a company getting bought out. Any insite as to what this could do?

1 · Reply

Subject02066 Nov. 5 at 2:50 PM

$EVOK sell or wait…😄

1 · Reply

Creyedr Nov. 5 at 1:56 PM

$VVOS $EVOK 100% Agree. Vivos is sitting on a goldmine. For me, this will be like $TARS .... 10x'd and still going because they met a treatment need that works for a common problem. Simple formula.

0 · Reply

Arthur715 Nov. 5 at 5:09 AM

$EVOK Todays monster nicee one

1 · Reply

glv570 Nov. 5 at 2:30 AM

$EVOK Still planty of room to make some 💰 Check APPS and EGHT .Both posted good earnings today

0 · Reply

TheRealShortSqueezy Nov. 5 at 2:21 AM

🔔‼Heads up !! 🔔‼ At 8am tomorrow, I’ll reveal a low float name under 1$ which has serious chart upside. The company just got transfered to be trading on Nasdaq Capital Market Stay tuned!⏳⏳ $FLYE $EVOK $DTCK $DENN $PTLE

1 · Reply

BULLETSTOCK Nov. 5 at 12:57 AM

$ADTX will be like $EVOK once we get the volume

1 · Reply

ChaseDeluca Nov. 4 at 11:31 PM

Watch VEEE 4am gapper potential $EVOK $DTCK $CMBM $PTLE

0 · Reply

ACInvestorBlog Nov. 4 at 10:38 PM

Why the Oral Devices Make $VVOS Attractive for Acquisition: First oral device cleared for severe OSA (Nov 2023) and pediatric moderate-to-severe OSA (Sep 2024), with Medicare coverage for all adult severities (Jul 2025). This unlocks reimbursement potential (~$45-120M annual scalability per analyst estimates) and positions VVOS as a disruptor. Market cap (~$17M as of late 2025) makes it a cheap tuck-in (<$50M deal value), especially with recent revenue traction. Paitience is key like in $EVOK

1 · Reply

mikesterz7 Nov. 4 at 10:17 PM

$EVOK Evoke noted that the deal reflects the strategic value of Gimoti, the company’s nasal spray for the treatment of symptoms of acute and recurrent diabetic gastroparesis in adults.

1 · Reply

topstockalerts Nov. 4 at 9:23 PM

Top Gainers $EVOK $DTCK $PTLE $CMBM $DENN

0 · Reply

RunnerSignals Nov. 4 at 9:22 PM

Market Buzz Alert $EVOK $TCMD $HTZ all blasting higher while $VSTM $PMTS slide https://stocksrunner.com/news/2025-11-04-top-5-movers-and-shakers-leading-the-buzz-today

0 · Reply

Market Cap	18.86M
Revenue (ttm)	10.25M
Net Income (ttm)	-5.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-52.20%
Debt to Equity Ratio	0.00

Volume	83,100
Avg Vol	113,882
Day's Range	N/A - N/A
Shares Out	1.72M
Stochastic %K	56%
Beta	-0.15
Analysts	Hold
Price Target	$10.00